C4 Therapeutics reports Q3 net loss $32.2M, raises $125M; cemsidomide 53% ORR at 100 µg

C4 Therapeutics, Inc.

2025-Q3 EPS reported -$1.18 revenue$24,931,000

Revenue $11.2M, net loss $32.2M ($0.44 EPS) vs $15.4M revenue and $24.7M loss in Q3 2024.
Completed equity offering of $125M gross proceeds in Oct 2025; potential additional $225M from warrants.
Phase 1 cemsidomide data: 53% ORR at 100 µg dose; one patient achieved MRD-negative complete response.
Entered clinical trial collaboration with Pfizer to evaluate cemsidomide + elranatamab; Pfizer supplies drug at no cost.
Cash $199.8M as of Sep 30, excluding $125M raise; runway extended to end of 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.